中国实验血液学杂志最新文献

{"title":"[Clinical Characteristics and Prognosis of B-cell Acute Lymphoblastic Leukemia Patients with <i>IKZF1</i> Deletion].","authors":"Li-Hua Wang, Yan Guo, Yuan Zhang, Xiu-Feng Wang, Xian-Kai Liu, Yan Huang","doi":"10.19746/j.cnki.issn.1009-2137.2025.04.006","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2025.04.006","url":null,"abstract":"<p><strong>Objective: </strong>To analyze clinical characteristics and prognosis of B-cell acute lymphoblastic leukemia (B-ALL) patients with <i>IKZF1</i> deletion.</p><p><strong>Methods: </strong>72 patients with B-ALL admitted to our hospital from April 2020 to January 2023 were selected, <i>IKZF1</i> deletion were detected, and clinical characteristics and prognosis were analyzed.</p><p><strong>Results: </strong>Among the 72 patients, a total of 32 patients (44.4%) were identified with <i>IKZF1</i> deletions (<i>IKZF1</i> ⁺ ). There was no statistically significant difference in basic clinical data between patients with normal <i>IKZF1</i> (<i>IKZF1</i> ^-) and those with <i>IKZF1</i> ⁺ (<i>P</i> >0.05). The proportion of patients with <i>IKZF1</i> ⁺ in Ph⁺ group was significantly higher than that in Ph^- group (<i>P</i> < 0.05). The main types of <i>IKZF1</i> ⁺ were exon 1-8 deletion (34.4%) and exon 4-7 deletion (31.2%). The median OS and PFS of <i>IKZF1</i> ^- patients were significantly longer than those of <i>IKZF1</i> ⁺ patients (OS: 26.0 months vs 16.0 months, <i>χ</i> ²=23.094, <i>P</i> < 0.05; PFS: 26.0 months <i>vs</i> 16.0 months, <i>χ</i> ²=11.150, <i>P</i> < 0.05). Among <i>IKZF1</i> ⁺ patients, the median OS of patients who received allogeneic hematopoietic stem cell transplantation (allo-HSCT) was significantly longer than that of patients who did not receive allo-HSCT (no reached <i>vs</i> 15.0 months, <i>χ</i> ²=5.685, <i>P</i> < 0.05).</p><p><strong>Conclusion: </strong><i>IKZF1</i> deletion is a risk factor affecting the prognosis of B-ALL patients.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 4","pages":"966-971"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145041639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Prognostic Significance of Monocyte Count in Patients with Non-Severe Aplastic Anemia].","authors":"Xue-Dong Shi, Li Han, Shu-Qi Wang, Qiu-Shuang Wang, Zhen-Yu Li, Kai-Lin Xu, Hai Cheng","doi":"10.19746/j.cnki.issn.1009-2137.2025.04.028","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2025.04.028","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the prognostic value of peripheral blood absolute monocyte count(AMC) in non-severe aplastic anaemia(NSAA) patients.</p><p><strong>Methods: </strong>178 patients with NSAA who attended the Affiliated Hospital of Xuzhou Medical University from April 2008 to September 2020 were retrospectively analyzed, and the optimal cut-off value of peripheral blood AMC was determined by the receiver operating characteristic curve of the subjects, and they were divided into low AMC group (48 patients) and normal AMC group (130 patients), and the differences in clinical characteristics between the two groups were compared. Overall survival(OS) and progression-free survival(PFS) were analyzed by Kaplan-Meier. Univariate and multivariate Cox regression analysis were used to determine the independent prognostic value of AMC.</p><p><strong>Results: </strong>Among 178 NSAA patients, 105(59.0%) were male and 73(41.0%) were female, with a median age of 31(18-87) years old, a median follow-up time of 58 months (range: 6 months-175 months), and a median AMC of 0.15×10⁹/L ［range: (0.01-0.59)×10⁹/L)］. The proportion of granulocytes (27.5% <i>vs</i> 36.0%, <i>P</i> < 0.05), and the proportion of mature monocytes (1% <i>vs</i> 2%, <i>P</i> < 0.05) in the low AMC group were lower than that in the normal AMC group; the proportion of mature lymphocytes in the low AMC group was higher than that in the normal AMC group (54% <i>vs</i> 50%, <i>P</i> < 0.05). However, there was no significantly different in the proportion of erythropoietic cells and stages of the erythropoietic cells between the two groups ( <i>P</i> >0.05). CR (27.7% <i>vs</i> 10.4%) and ORR (75.4% <i>vs</i> 56.3%) in the normal AMC group were higher than that in the low AMC group. Compared with patients in the low AMC group, AA patients in the normal AMC had better 5-year OS (98.5% <i>vs</i> 86.9%, <i>P</i> < 0.01), and the 5-year PFS (86.0% <i>vs</i> 58.9%, <i>P</i> < 0.01). Also, the 10-year survival rate of patients in the normal AMC group was higher than that in the low AMC group (98.5% <i>vs</i> 60.5%,<i>P</i> < 0.01). Univariate analysis showed that age, reticulocyte count, AMC<0.1×10⁹/L and the proportion of bone marrow mature monocytes were related with patients survival. Multivariate Cox regression analysis showed that monocyte count reduction was not an independent poor prognostic factor in NSAA patients （<i>HR</i> =4.474，95%<i>CI</i> ：0.508-44.390； <i>P</i> =0.172）.</p><p><strong>Conclusion: </strong>Low AMC level at initial diagnosis is not an independent prognostic factor for NSAA patients, but still suggest potential prognostic value of AMC.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 4","pages":"1120-1126"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145041717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Correlation Analysis of Inflammatory Indexes and Bone Marrow Cytological Characteristics with Prognosis in Patients with Hemophagocytic Lymphohistiocytosis].","authors":"Guo-Xiang Chen, Jian-Shu Hao, Qing-Qing Zhang, Hai-Xia An, Yan-Qing Sun, Xiu-Juan Huang","doi":"10.19746/j.cnki.issn.1009-2137.2025.04.023","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2025.04.023","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the clinical characteristics and prognosis of patients with hemophagocytic lymphohistiocytosis (HLH).</p><p><strong>Methods: </strong>Clinical data of 78 patients with HLH admitted to Gansu Provincial People's Hospital from January 2014 to May 2023 were collected, and the correlation between relevant indicators and patient prognosis was analyzed.</p><p><strong>Results: </strong>Among the 78 HLH patients, there were 48 males and 30 females, with a median age of onset of 48 (1-84) years old; 26 patients were treated with chemotherapy, 44 patients were treated with glucocorticoids, immunoglobulin or cyclosporine, 5 patients received symptomatic treatment, 1 patient received plasma exchange, and 2 patients refused treatment. By the end of the follow-up, there were 39 survivors, 35 deaths, and 4 patients lost to follow-up. There was no significant correlation between sex, ferritin, triglycerides, hemophagocytosis, bone marrow cellularity, Epstein-Barr virus (EBV) infection, SUV value of PET-CT, alanine aminotransferase (ALT), interleukin-6 (IL-6), platelet-to-lymphocyte ratio (PLR) and overall survival (OS) of the patients (<i>P</i> >0.05). Patients with age≥60 years, neutrophil-to-lymphocyte ratio (NLR) >0.59, red cell distribution width-to-platelet ratio (RPR) >0.30, lymphocyte-to-monocyte ratio (LMR)≤2.74, red blood cell distribution width (RDW)>16.45%, tumor-associated HLH, aspartate aminotransferase (AST)≥148 U/L, procalcitonin (PCT)≥0.66 ng/ml, neutrophils (NEU) <2×10⁹/L, fibrinogen (FIB)<1.85 g/L, lactate dehydrogenase (LDH)≥1 740 U/L, hemoglobin (Hb)<85 g/L, platelet (PLT)<57×10⁹/L had significantly shorter OS, with statistical significance (<i>P</i> < 0.05). Multivariate analysis showed that LMR≤2.74, RDW>16.45%, LDH≥1 740 U/L, and NEU<2×10⁹/L were independent risk factors affecting OS in HLH patients (<i>P</i> < 0.05).</p><p><strong>Conclusion: </strong>Some blood-based inflammatory markers are significantly associated with OS in patients with HLH. NLR, RPR, LMR, RDW and PCT can be used to assess the prognosis of HLH patients, and RDW and LMR are independent factors affecting OS of HLH patients, which provide greater predictive value for prognosis. Hypercellular bone marrow in HLH patients may indicate a poor prognosis.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 4","pages":"1086-1093"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145041667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Effect of <i>LINC00641</i> on Viability and Apoptosis of Acute Myeloid Leukemia Cells].","authors":"Yun-Ling Zhang, Ying Yang, Yin Sun, Hong-Li Chai","doi":"10.19746/j.cnki.issn.1009-2137.2025.04.010","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2025.04.010","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effect of <i>LINC00641</i> on the viability and apoptosis of acute myeloid leukemia (AML) cells and its mechanism.</p><p><strong>Methods: </strong>RT-qPCR was applied to detect the relative expression levels of <i>LINC00641</i>, miR-204-5p, and <i>MT1X</i> in human normal bone marrow stromal cell lines HS-5 and AML cell lines, and to screen the optimal cell line THP-1 was screened for subsequent experiments. Bioinformatics, dual luciferase reporter assay, pull down assay, and RIP assay were applied to validate the targeting relationship between <i>LINC00641</i>, <i>MT1X</i> and miR-204-5p. EdU, CCK-8, flow cytometry, and Transwell assay were applied to detect cell proliferation, apoptosis, migration and invasion, respectively. Western blot was applied to detect the expression of <i>MT1X</i> , CyclinD1, Bcl-2, and Bax proteins.</p><p><strong>Results: </strong>Compared with HS-5 cells, the expression of <i>LINC00641</i> and <i>MT1X</i> was obviously increased in HL60, THP-1, U937, and KG1 cells, while the expression of miR-204-5p was obviously reduced (all <i>P</i> <0.05). THP-1 cells showed the most obvious changes (<i>P</i> <0.05). Silencing <i>LINC00641</i> or overexpressing miR-204-5p was able to obviously inhibit the proliferation, migration and invasion of THP-1 cells, as well as the expression of CyclinD1 and Bcl-2 proteins, while promote cells apoptosis and Bax protein expression (all <i>P</i> <0.05). Bioinformatics analysis, dual luciferase reporter assay, pull down assay, and RIP assay all confirmed that there were targeted relationships between <i>LINC00641</i>, <i>MT1X</i> and miR-204-5p. Inhibiting miR-204-5p or overexpressing <i>MT1X</i> was able to respectively reverse the inhibitory effect of silencing <i>LINC00641</i> or overexpressing miR-204-5p on THP-1 cells proliferation, migration and invasion, and reduce cells apoptosis.</p><p><strong>Conclusion: </strong><i>LINC00641</i> is highly expressed in AML, and inhibition of <i>LINC00641</i> expression can inhibit cell proliferation, migration, and invasion and increase apoptosis by regulating the miR-204-5p/<i>MT1X</i> axis.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 4","pages":"998-1006"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145041697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Efficacy and Safety of Zanubrutinib in the Treatment of Autoimmune Cytopenia Secondary to Indolent B-Cell Lymphoma].","authors":"Xiao-Pei Wang, Wei-Wei Zhang, Wei Sun, Jia-Feng Cheng","doi":"10.19746/j.cnki.issn.1009-2137.2025.04.013","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2025.04.013","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the efficacy and safety of zanubrutinib in the treatment of autoimmune cytopenia (AIC) secondary to indolent B-cell lymphoma (iBCL).</p><p><strong>Methods: </strong>A total of 23 patients with iBCL complicated with AIC who were admitted to our hospital from December 2019 to September 2023 were selected as the research subjects. All patients were administered zanubrutinib 160 mg, twice daily, and continued oral administration. The objective response rate (ORR) of AIC, the therapeutic effect on lymphoma, and the incidence of adverse reactions were observed.</p><p><strong>Results: </strong>After a median follow-up of 20 (5 to 48) months, the median duration of response was 9 (interquartile range [IQR] 5-24)months. AICA efficacy assessment showed that there were 10 cases of complete remission (CR), 9 cases of partial remission (PR), and 4 cases of no response (NR), and the ORR was 82.6% (19/23) (95%<i>CI</i> : 61.2-95.0). Among them, for the 14 patients with autoimmune hemolytic anemia (AIHA), 7 achieved CR, 5 had PR, and 2 had NR. For the 4 patients with immune thrombocytopenia (ITP), 1 reached CR, 2 had PR, and 1 had NR. Regarding the 5 patients with Evans syndrome (ES), 2 achieved CR, 2 had PR, and 1 had NR. The assessment of lymphoma efficacy showed that there were 10 cases of CR , 7 cases of PR , 6 cases of stable disease (SD), and no progressive cases, with an ORR of 73.9% (17/23) (95%<i>CI</i> : 51.6-89.8). The main adverse reactions during the treatment were infection, hemorrhage, neutropenia, elevated lymphocyte count, rash, and anemia. Most of these adverse reactions were grade 1-2 and tolerable. No arrhythmia and hypertension occurred, and no deaths due to adverse reactions.</p><p><strong>Conclusion: </strong>Zanubrutinib is effective and safe for AIC secondary to iBCL.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 4","pages":"1023-1028"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145040906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[PD-1 Inhibitor Combined with Azacitidine and HAG Regimen for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia: A Prospective, Single-Arm, Phase II Clinical Study].","authors":"Cheng-Sen Cai, Ru-Ju Wang, Xiao-Yan Xu, Cheng-Yuan Gu, Hui-Zhu Kang, Yue-Jun Liu, Yue Han","doi":"10.19746/j.cnki.issn.1009-2137.2025.04.007","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2025.04.007","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the efficacy and safety of PD-1 inhibitor combined with azacitidine and HAG regimen in the treatment of relapsed/refractory acute myeloid leukemia (R/R AML).</p><p><strong>Methods: </strong>This study is a prospective, single-arm, phase II clinical trial that included R/R AML patients who met the inclusion criteria and were treated at The First Affiliated Hospital of Soochow University from December 2020 to August 2023. Patients could undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT) after salvage therapy. The efficacy and safety were evaluated.</p><p><strong>Results: </strong>Twenty patients were enrolled, including 14 males and 6 females, with an average age of (50.7±15.3) years. The overall response rate (ORR) after one cycle of the treatment was 75.0% (15/20), and 35.0% (7/20) of the patients achieved complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) after two cycles of the treatment. Eight patients received allo-HSCT. The main adverse events were hematologic toxicities, and no grade 5 adverse events occurred.</p><p><strong>Conclusion: </strong>The combination of PD-1 inhibitor, azacitidine, and the HAG regimen is a feasible and relatively safe treatment option for R/R AML, thus, to be worth further study.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 4","pages":"972-979"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145041608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The Role of the Modified Endothelial Activation and Stress Index (mEASIX) in Predicting the Efficacy of CAR-T Cell Therapy and Cytokine Release Syndrome (CRS)].","authors":"Jin Hu, Qian-Nan Han, Feng-Yi Lu, Xin-Yue Zhou, Zhi-Qin Yang, Kai-Lin Xu, Wei Chen","doi":"10.19746/j.cnki.issn.1009-2137.2025.04.039","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2025.04.039","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the predictive role of the modified Endothelial Activation and Stress Index (mEASIX) in the efficacy of chimeric antigen receptor T-cell (CAR-T) therapy and cytokine release syndrome (CRS).</p><p><strong>Methods: </strong>The clinical data of 70 relapsed and refractory (R/R) B-cell tumor patients who were treated with CAR-T therapy from September 1, 2018 to February 28, 2023 in the Department of Hematology, Affiliated Hospital of Xuzhou Medical University, were retrospectively analyzed. The value of log-2 mEASIX before conditioning (-7 d) was calculated, and the patients were divided into a low-mEASIX group (42 patients) and a high-mEASIX group (28 patients) based on the cut-off value of 5.443 determined by the receiver operating characteristic (ROC) curve. Eventually, the predictive role of mEASIX before conditioning on the efficacy of CAR-T cell therapy and CRS was analyzed.</p><p><strong>Results: </strong>The high-mEASIX group exhibited significantly worse median overall survival (OS) and median progression-free survival (PFS) in comparison to the low mEASIX group (OS: 3.2 months <i>vs</i> not reached, <i>P</i> < 0.01; PFS: 1.3 months <i>vs</i> 6.0 months, <i>P</i> =0.009). The incidence of grade ≥2 CRS in the high-mEASIX group was substantially higher than that in the low-mEASIX group (57.1% <i>vs</i> 19.0%, <i>P</i> =0.007). The degree of remission after CAR-T therapy (<i>P</i> =0.001), whether CRS occurs or not (<i>P</i> =0.041), the lactate dehydrogenase (LDH) level before conditioning (<i>P</i> =0.046), and the mEASIX score before conditioning (<i>P</i> =0.047) were independent influencing factors for the OS of patients receiving CAR-T cell therapy.</p><p><strong>Conclusion: </strong>The mEASIX score before conditioning can predict OS and the incidence of grade ≥2 CRS in patients with relapsed and refractory B-cell tumors who receive CAR-T cell therapy.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 4","pages":"1190-1198"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145041673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The Value of Thrombus Biomarkers for Assessing the Progression of Immunoglobulin A Vasculitis in Children].","authors":"Fang Chen, Han-Jun Shen, Cheng Wang, Liang-Yue Chen, Jian Xue, Jia Wei","doi":"10.19746/j.cnki.issn.1009-2137.2025.04.027","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2025.04.027","url":null,"abstract":"<p><strong>Objective: </strong>To explore the significance of thrombus biomarkers in evaluating the progression of immunoglobulin A vasculitis (IgAV) in children.</p><p><strong>Methods: </strong>A total of 193 children who were diagnosed as IgAV from September 2021 to June 2023 in the Children's Hospital of Soochow University were enrolled. The levels of plasma thrombomodulin (TM), thrombin-antithrombin complex (TAT), plasmin-α2-plasmin inhibitor complex (PIC), tissue plasminogen activator-plasminogen activator inhibitor-1 complex (t-PAIC) and D-dimer (D-D) were analyzed retrospectively. And, 140 healthy children were selected as controls during the same period. The receiver operating characteristic (ROC) curves were drawn to analyze the role of thrombus parameters in estimating the progression of IgAV in children. Univariate and multivariate logistic regression analysis were used to assess the independent risk factors influencing the progression of pediatric IgAV in acute phase.</p><p><strong>Results: </strong>The levels of D-D, TAT, PIC and t-PAIC in plasma of IgAV group were higher than those in control group (all <i>P</i> <0.001). The levels of D-D, TAT and PIC in acute phase children were significantly higher than those in non acute phase children (all <i>P</i> <0.001), while the levels of kidney injury related indicators such as 24h-UTP, urine albumin/creatinine ratio, positive urinary blood on dipstick, serum creatinine and cystatin C were lower (all <i>P</i> <0.05). ROC analysis showed that the area under curve (AUC) of PIC was 0.743 when the cut-off value was 0.93 μg/ml with 71.8% sensitivity and 78.3% specificity, while the AUC of D-D was 0.756 when the cut-off value was 550.0 μg/L with 81.3% sensitivity and 73.4% specificity. Univariate and multivariate logistic regression analysis showed that PIC≥0.93 μg/ml (<i>OR</i> =4.64, <i>P</i> =0.012) and D-D≥550.0 μg/L (<i>OR</i> =3.60, <i>P</i> =0.035) were the independent risk factors for the progression of IgAV in acute phase.</p><p><strong>Conclusion: </strong>The pediatric patients with IgAV have shown hyperfibrinolysis in the acute stage. Furthermore, the levels of PIC and D-D should be of diagnostic value for evaluating the progression of IgAV in the acute phase.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 4","pages":"1113-1119"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145041675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Establishment and Mechanistic Study of Venetoclax-Resistant Cell Lines in Acute Myeloid Leukemia].","authors":"Kai-Fan Liu, Ling-Ji Zeng, Su-Xia Geng, Xin Huang, Min-Ming Li, Pei-Long Lai, Jian-Yu Weng, Xin DU","doi":"10.19746/j.cnki.issn.1009-2137.2025.04.009","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2025.04.009","url":null,"abstract":"<p><strong>Objective: </strong>To establish venetoclax-resistant acute myeloid leukemia (AML) cell lines, assess the sensitivity of venetoclax-resistant cell lines to the BCL-2 protein family, and investigate their resistance mechanisms.</p><p><strong>Methods: </strong>CCK-8 method was used to screen AML cell lines (MV4-11, MOLM13, OCI-AML2) that were relatively sensitive to venetoclax. Low concentrations of venetoclax continuously induced drug-resistance development in the cell lines. Changes in cell viability and apoptosis rate before and after resistance development were measured using the CCK-8 method and flow cytometry. BH3 profiling assay was performed to anayze the transform of mitochondrion-dependent apoptosis pathway as well as the sensitivity of resistant cell lines to BCL-2 family proteins and small molecule inhibitors. Real-time fluorescence quantitative PCR (RT-qPCR) was utilized to examine changes in the expression levels of BCL-2 protein family members in both venetoclax-resistant cell lines and multidrug-resistant patients.</p><p><strong>Results: </strong>Venetoclax-resistant cell lines of MV4-11, MOLM13, and OCI-AML2 were successfully established, with IC₅₀ values exceeding 10-fold. Under the same concentration of venetoclax, the apoptosis rate of resistant cells decreased significantly (<i>P</i> < 0.05). BH3 profiling assay revealed that the drug-resistant cell lines showed increased sensitivity to many pro-apoptotic proteins (such as BIM,BID and NOXA). RT-qPCR showed significantly upregulated <i>MCL1</i> and downregulated <i>NOXA1</i> were detected in drug-resistant cell lines. Expression changes in <i>MCL1</i> and <i>NOXA1</i> in venetoclax-resistant patients were consistent with our established drug-resistant cell line results.</p><p><strong>Conclusion: </strong>The venetoclax-resistant AML cell lines were successfully established through continuous induction with low concentrations of venetoclax. The venetoclax resistance resulted in alterations in the mitochondrial apoptosis pathway of the cells and an increased sensitivity of cells to pro-apoptotic proteins BIM, BID, and NOXA, which may be associated with the upregulation of <i>MCL1</i> expression and downregulation of <i>NOXA1</i> expression in the drug-resistant cells.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 4","pages":"986-997"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145040871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Correlation Analysis between Immune Cells in Graft and Early Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation].","authors":"Shan Wang, Fan Liu, Qiu-Juan Zhu, Tao Wang, Rong Gong, Wei-Wei Tian, Zhi-Lin Gao","doi":"10.19746/j.cnki.issn.1009-2137.2025.04.037","DOIUrl":"10.19746/j.cnki.issn.1009-2137.2025.04.037","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the correlation between the types and quantities of immune cells in the graft and early immune reconstitution after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and their influence on clinical prognosis.</p><p><strong>Methods: </strong>The clinical data of 83 patients with hematological diseases who received allo-HSCT in Shanxi Bethune Hospital from September 2020 to June 2023 were retrospectively analyzed. The number of mononuclear cells (MNC), CD34⁺ cells and lymphocyte subsets (including CD3⁺T, CD3⁺CD4⁺T(Th), CD3⁺CD8⁺T(Ts), NK cells and B cells) infused into the recipients was counted, and the peripheral blood lymphocytes were detected before conditioning and on days 14, 30, 60 and 100 post-HSCT.</p><p><strong>Results: </strong>Multivariate analysis showed that the number of MNC in the graft affected the recovery of CD4⁺T lymphocytes after HSCT, and the number of CD4⁺T lymphocytes in the graft affected the recovery of NK cells and B cells after HSCT. The patient age, donor sex, stem cell source, degree of HLA matching, use of ATG before HSCT, the occurrence of acute graft-versus-host disease (aGVHD) after HSCT, and viral infection all affect the early cellular immune reconstitution post-HSCT. The number of infused cells had no significant impact on the median engraftment time for neutrophils and platelets after HSCT. Patients with lower numbers of CD3⁺T, CD4⁺T and B cells in the graft were more prone to viral infection after HSCT. However, the cells in the graft had no significant effect on disease recurrence or mortality.</p><p><strong>Conclusion: </strong>The recovery rate of lymphocyte count after allo-HSCT varies. The numbers of MNC and CD4⁺T cells in the graft may be related to the cellular immune reconstitution after HSCT, while the numbers of CD34⁺,CD3⁺T,CD8⁺T,NK and B cells have no significant effect on the cellular immune reconstruction. The numbers of CD3⁺T,CD4⁺T and B cells in the graft were negatively correlated with viral infection after HSCT, but the cellular components of the graft have no obvious influence on hematopoietic reconstitution, disease recurrence, death, recurrence-free survival(RFS) and overall survival(OS) after HSCT.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 4","pages":"1173-1180"},"PeriodicalIF":0.0,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145041678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}